Dréno B, Claudy A, Meynadier J, Verret J L, Souteyrand P, Ortonne J P, Kalis B, Godefroy W Y, Beerblock K, Thill L
Department of Dermatology, CHU Nantes, France.
Br J Dermatol. 1991 Nov;125(5):456-9. doi: 10.1111/j.1365-2133.1991.tb14772.x.
Forty-five patients with cutaneous T-cell lymphomas (CTCL), 32 with mycosis fungoides (MF) and 13 with Sézary syndrome (SS), were treated with interferon-alpha 2a (IFN-alpha 2a) (6-9 x 10(6) IU daily) for 3 months. Those responding to treatment were then treated with interferon-alpha alone (6-9 x 10(6) IU three times weekly), and non-responders received a combination of etretinate (0.5 mg/kg/day) and IFN-alpha 2a in similar concentrations. After 12 months of treatment, 28/45 patients (62.2%) were in complete or partial (greater than 50%) remission. Of these, 17 (60.7%) were receiving IFN-alpha alone and 11 the combined interferon-retinoid therapy. Of the patients with MF stage I and II, 20/25 were responders (12 receiving IFN-alpha alone and eight on combined therapy), whereas only 8/20 with stage IV or SS responded to treatment (five receiving IFN-alpha 2a alone and three combined therapy). These results suggest that the association of etretinate with low-dose recombinant IFN-alpha 2a is an effective means of treating epidermotropic CTCL, particularly in the early stages.
45例皮肤T细胞淋巴瘤（CTCL）患者，其中32例蕈样肉芽肿（MF）患者和13例塞扎里综合征（SS）患者，接受了α-2a干扰素（IFN-α2a）（每日6 - 9×10⁶IU）治疗3个月。对治疗有反应的患者随后单独接受α-干扰素治疗（每周三次，每次6 - 9×10⁶IU），无反应者接受依曲替酯（0.5mg/kg/天）和相似浓度的α-2a干扰素联合治疗。治疗12个月后，28/45例患者（62.2%）达到完全或部分（大于50%）缓解。其中，17例（60.7%）仅接受α-干扰素治疗，11例接受干扰素-维甲酸联合治疗。在I期和II期MF患者中，20/25例有反应（12例仅接受α-干扰素治疗，8例接受联合治疗），而IV期或SS患者中仅有8/20例对治疗有反应（5例仅接受α-2a干扰素治疗，3例接受联合治疗）。这些结果表明，依曲替酯与低剂量重组α-2a干扰素联合使用是治疗亲表皮性CTCL的有效方法，尤其是在疾病早期。
